0001209191-22-061923.txt : 20221219 0001209191-22-061923.hdr.sgml : 20221219 20221219163043 ACCESSION NUMBER: 0001209191-22-061923 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20221215 FILED AS OF DATE: 20221219 DATE AS OF CHANGE: 20221219 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Woosley Raymond L. CENTRAL INDEX KEY: 0001582095 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-22873 FILM NUMBER: 221471491 MAIL ADDRESS: STREET 1: C/O ARCA BIOPHARMA, INC. STREET 2: 8001 ARISTA PLACE, STE 430 CITY: BROOMFIELD STATE: CO ZIP: 80021 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: ARCA biopharma, Inc. CENTRAL INDEX KEY: 0000907654 STANDARD INDUSTRIAL CLASSIFICATION: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835] IRS NUMBER: 363855489 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 10170 CHURCH RANCH WAY STREET 2: SUITE 100 CITY: WESTMINSTER STATE: CO ZIP: 80021 BUSINESS PHONE: 7209402200 MAIL ADDRESS: STREET 1: 10170 CHURCH RANCH WAY STREET 2: SUITE 100 CITY: WESTMINSTER STATE: CO ZIP: 80021 FORMER COMPANY: FORMER CONFORMED NAME: NUVELO INC DATE OF NAME CHANGE: 20030203 FORMER COMPANY: FORMER CONFORMED NAME: HYSEQ INC DATE OF NAME CHANGE: 19970610 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2022-12-15 0 0000907654 ARCA biopharma, Inc. ABIO 0001582095 Woosley Raymond L. 10170 CHURCH RANCH WAY SUITE 100 WESTMINSTER CO 80021 1 0 0 0 Stock Option (right to buy) 2.32 2022-12-15 4 A 0 6000 0.00 A 2032-12-15 Common Stock 6000 6000 D Grant to the Reporting Person of a stock option under the 2020 Equity Incentive Plan, vesting in 12 equal monthly installments beginning as of December 15, 2022. If the Reporting Person's service as a director of the Issuer terminates in connection with or at any time following a change in control (for whatever reason), then any unexpired options that remain unvested shall become fully vested. /s/ C. Jeffrey Dekker, Attorney-in-Fact 2022-12-19 EX-24 2 poa.txt POA DOCUMENT POWER OF ATTORNEY Know all by these presents, that the undersigned hereby constitutes and appoints each of Michael R. Bristow, Thomas A. Keuer, Christopher D. Ozeroff, Brent D. Fassett and Savir Punia, signing individually, the undersigned's true and lawful attorneys-in fact and agents to: (1) execute for and on behalf of the undersigned, in the undersigned's capacity as an executive officer, member of the Board of Directors and/or greater than 10% stockholder of ARCA biopharma, Inc. (the "Company"), Forms 3, 4 and 5 (including any amendments thereto) in accordance with Section 16(a) of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and the rules thereunder; (2) do and perform any and all acts for and on behalf of the undersigned which may be necessary or desirable to complete and execute any such Forms 3, 4 or 5 (including any amendments thereto) and timely file such forms with the Securities and Exchange Commission and any stock exchange or similar authority; and (3) take any other action of any nature whatsoever in connection with the foregoing which, in the opinion of such attorney-in-fact, may be of benefit to, in the best interest of, or legally required by, the undersigned, it being understood that the documents executed by such attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as such attorney-in-fact may approve in such attorney-in-fact's discretion. The undersigned hereby grants to each such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that such attorney-in-fact, or such attorney-in-fact's substitute or substitutes, shall lawfully do or cause to be done by virtue of this power of attorney and the rights and powers herein granted. The undersigned acknowledges that the foregoing attorneys-in-fact, in serving in such capacity at the request of the undersigned, are not assuming, nor is the Company assuming, any of the undersigned's responsibilities to comply with Section 16 of the Exchange Act. This Power of Attorney shall remain in full force and effect until the earliest to occur of (a) the undersigned is no longer required to file Forms 3, 4 and 5 with respect to the undersigned's holdings of and transactions in securities issued by the Company, (b) revocation by the undersigned in a signed writing delivered to the foregoing attorneys-in-fact, or (c) as to any attorney-in-fact individually, until such attorney-in-fact is no longer employed by the Company or employed by or a partner at Wilson Sonsini Goodrich & Rosati, as applicable. The undersigned has caused this Power of Attorney to be executed as of December 15, 2022. /s/ Ray Woosley ________________________________ Ray Woosley